Welcome to our dedicated page for Lineage Cell The news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell The stock.
Lineage Cell Therapeutics Inc. (LCTX) is a clinical-stage biotechnology leader developing novel cell-based therapies for degenerative diseases. This dedicated news hub provides investors and stakeholders with timely updates on corporate developments, clinical research progress, and regulatory milestones.
Access authoritative information about LCTX's innovative platforms in cell replacement therapies and targeted drug delivery systems. Our curated collection features press releases covering clinical trial results, strategic partnerships, intellectual property updates, and scientific presentations.
Stay informed about advancements in treatments for retinal degeneration, spinal cord injuries, and oncology applications. All content is verified at source, ensuring reliable tracking of the company's progress in regenerative medicine. Bookmark this page for streamlined access to essential updates impacting LCTX's position in the biotech sector.
Lineage Cell Therapeutics (NYSE American: LCTX) announced positive interim results from its Phase 1/2a clinical study of OpRegen, a cell therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA). In Cohort 4, 75% of patients showed maintained or improved visual acuity, with enhancements of up to +19 letters on an EDTRS chart. Notably, OpRegen has exhibited durability, with some patients demonstrating stable outcomes after over 5 years. The study utilized minimal immunosuppression, with no unexpected adverse events reported, suggesting potential for effective long-term treatment.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX) announced that CEO Brian M. Culley will present at the Benzinga Global Biotech Small Cap conference on March 24, 2021, at 11:50 AM ET. He will also participate in a panel discussion titled “Coming Together to Address Unmet Medical Needs” at 12:50 PM ET. Investors can register for the event in advance at Benzinga's website. The event's webcasts will be accessible on Lineage's Events and Presentations page.
Lineage Cell Therapeutics (LCTX) announced its fourth quarter and full year 2020 financial results, highlighting significant clinical and operational milestones. Total revenues decreased to $1.8 million for 2020, down from $3.5 million in 2019. Operating expenses were $27.9 million, a reduction of $14.1 million year-over-year. The net loss for 2020 was $20.6 million, or $0.14 per share. Importantly, Lineage secured $35.9 million in new capital, strengthening its financial position. The company aims to continue advancing its pipeline with key FDA meetings and clinical data presentations planned for 2021.
Lineage Cell Therapeutics, Inc. (LCTX) has raised $36 million through liquidating marketable securities and an at-the-market offering to fund operations through 2023. The company reported $57 million in cash and cash equivalents as of March 5, 2021. CEO Brian Culley emphasized value creation via these sales and advancing product candidates. Lineage's strong balance sheet provides flexibility for partnership discussions. Additionally, it has realized $32.5 million from OncoCyte share sales, holding shares currently valued at around $4.2 million.
Lineage Cell Therapeutics (LCTX), a clinical-stage biotechnology firm, will announce its Q4 and full-year 2020 financial results on March 11, 2021, after U.S. market close. A conference call at 4:30 PM ET will follow, discussing these results and providing a business update. Known for its proprietary cell-based therapy platform, Lineage is advancing three allogeneic product candidates, including therapies for dry age-related macular degeneration and spinal cord injuries. The company aims to address significant medical needs in billion-dollar markets.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX) announced that CEO Brian M. Culley will present at the Raymond James 42nd Annual Institutional Investors Conference on March 1, 2021, at 11:40 AM Eastern Time. He will also present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. Investors can access live and archived webcasts of these events on Lineage's Events and Presentations page.
Lineage Cell Therapeutics (NYSE American: LCTX) has announced a virtual Investor and Analyst Day scheduled for February 22, 2021, focusing on its OPC1 program aimed at treating acute spinal cord injuries. This program, which has received a $14.3 million grant from the California Institute for Regenerative Medicine, utilizes oligodendrocyte progenitor cell transplants to enhance motor recovery. The event will feature Dr. Edward Wirth, III, who will provide insights into the clinical data and discuss the ongoing partnership with Neurgain Technologies. Investors can access the live webcast through Lineage's website.
Lineage Cell Therapeutics (LCTX) has signed an exclusive option and license agreement with Neurgain Technologies. The collaboration focuses on clinical testing of Neurgain's innovative Parenchymal Delivery Injection (PDI) system for administering OPC1, a cell therapy for spinal cord injury. The PDI aims to simplify procedures by eliminating the need to stop respiration during surgery, potentially enhancing safety and effectiveness. Lineage's CEO emphasizes that this advancement complements their ongoing work on OPC1, which has received RMAT and Orphan Drug designations from the FDA.
Lineage Cell Therapeutics (LCTX) recently updated investors on its clinical advancements through webinars hosted by FORCE Wealth. The presentations covered three key product programs: OpRegen for dry age-related macular degeneration, OPC1 for acute spinal cord injuries, and VAC2 for cancer treatment. CEO Brian M. Culley emphasized the growing viability and market opportunity for allogeneic cell therapies. The company is gearing up for later-stage clinical trials, aiming to leverage supportive public policies and investor interest in cell therapy.
Lineage Cell Therapeutics (NYSE American: LCTX) announced the resignation of CFO Brandi Roberts on January 15, 2021, to pursue a leadership role elsewhere. She will assist in the transition as Brian Culley, the current CEO, steps in as Interim CFO. Brian praised Roberts for her contributions to restructuring and strengthening the company. Lineage is focused on developing allogeneic cell therapies for significant medical needs and has ongoing clinical programs targeting major health issues, including dry age-related macular degeneration and spinal cord injuries.
FAQ
What is the current stock price of Lineage Cell The (LCTX)?
What is the market cap of Lineage Cell The (LCTX)?
